Clinical Trials List
2026-03-01 - 2029-01-25
Phase III
Recruiting7
A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)
-
Trial Applicant
ELI LILLY AND COMPANY(TAIWAN), INC.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/09/10
Investigators and Locations
Co-Principal Investigator
- 吳孟晃 無
- Tzn-Min Lin 無
- 李向嚴 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 張皓翔 無
- 江建勰 無
- Kuo-Chin Huang 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 尤珊富 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
預充填式注射劑
Active Ingredient
Placebo
Dosage Form
230
Dosage
Endpoints
結果測量測量說明：體重自基準期以來的百分比變化
時間範圍：基準期，第64週
結果測量：西安大略及麥肯馬司特大學退化性關節炎量表(WOMAC)疼痛子量表分數自基準期以來的變化
結果測量測量說明：WOMAC疼痛子量表分數自基準期以來的變化
時間範圍：基準期，第64週
Inclution Criteria
Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening
Have a stable body weight (less than 5% body weight change) for 90 days prior to screening
Have tried at least once to lose weight through diet but were unsuccessful
Have osteoarthritis of the knee and at least one of the following conditions:
Be over 50 years old
Have morning knee stiffness that lasts about 30 minutes
Have a crackling or grinding sound or feeling in the knee
Exclusion Criteria
Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening)
Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
Have an active knee infection
Have had within 90 days prior to screening:
heart attack
stroke
coronary artery revascularization
unstable angina, or
hospitalization due to congestive heart failure
Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
Have taken medications or alternative remedies intended for weight loss within 90 days of screening
The Estimated Number of Participants
-
Taiwan
69 participants
-
Global
900 participants
